Hepatology Communications

Article	Citations
Development and evaluation of a virtual reality driving test for patients with cirrhosis	221
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	164
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	140
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	101
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	87
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	85
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	83
Association between widespread pain and associated symptoms in patients with cirrhosis	81
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	74
Issue Information	66
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	64
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	61
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	61
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	61
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	56
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	55
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	55
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	54
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	54
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	53
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study	52
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	52
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	52
Depression and anxiety management in cirrhosis	51
Granulomatous liver diseases	49

Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	49
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	46
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	45
Complementary and alternative medicines and liver disease	44
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	44
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	43
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action	42
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	42
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	42
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	42
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	41
Visualizing in situ viral replication across the natural history of chronic HBV infection	41
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	40
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	40
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	39
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	38
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	38
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing	38
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	36
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?	36
CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway	36
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	36
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis	35
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta	35
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”	34
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers	34
TGFβ‐induced FOXS1 controls epithelial–mesenchymal transition and predicts a poor prognosis in liver cancer	34
Lipid droplet deposition in the regenerating liver: A promoter, inhibitor, or bystander?	33
Immunoglobulin M: A Neglected Serum Biomarker in Treatment‐Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase	33
Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age	33
Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)	33
Intestinal virome in patients with alcohol use disorder and after abstinence	32
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis	32
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	32
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells	31
Increased MASH-associated liver cancer in younger demographics	31
Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy	31
Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver	31
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	30
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	30
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	30
CD36 in liver diseases	30
High prevalence of liver fibrosis among general population: a Romanian population-based study: Erratum	30
Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis	29
Loss of heat shock factor 1 promotes hepatic stellate cell activation and drives liver fibrosis	28
Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease	28
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease	27
Alpha-fetoprotein: Past, present, and future	27
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC	27
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	26

Hepatocyte TGF‐β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let‐7b‐5p	26
An Analysis of Free‐Text Refusals as an Indicator of Readiness to Accept Organ Offers in Liver Transplantation	26
Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review	26
Liver Cancer Has a Distinctive Profile in Black Patients: Current Screening Guidelines May Be Inadequate	26
Hepcidin Signaling in Health and Disease: Ironing Out the Details	26
Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins	25
Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis	25
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy	25
Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS	24
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021	24
The Matrisome Genes From Hepatitis B–Related Hepatocellular Carcinoma Unveiled	24
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives	24
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways thro	24
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis	23
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial	23
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning	23
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance	23
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study	23
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance	22
Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans	22
Erratum: Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children	22
Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis	22
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites	22
Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis	22
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study	22
	22
CD4+ T-cell subsets in autoimmune hepatitis: A review	22
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis	21
Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies	21
Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis	21
Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs	21
Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients	21
High Prevalence of Transjugular Intrahepatic Portosystemic Shunt Creation Without Prior Endoscopy During Acute Variceal Bleeding Hospitalization in the United States	21
Erratum: Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality	21
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment	21
	20
	20
Reply: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?	20
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways	20
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria: Erratum	20
Hepatology Communications Achieves First Impact Factor and MEDLINE Indexing	20
Erratum: Use and outcome of transjugular intrahepatic portosystemic shunt in hospitalized patients Germany:Nationwide study (2007-2018)	20
Acute on chronic liver failure: prognostic models and artificial intelligence applications	20
Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease	19
Aspirin is associated with a reduced incidence of liver disease in men	19
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid	19
Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2−/− mouse model of sclerosing cholangitis via immunomodulatory effects	19
Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?	19
Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction	19
Smartphone Apps to Stratify the Risk of Early Allograft Failure Are Just the Beginning for Next‐Generation Outcome Prediction in Transplantation Medicine	19
A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction–associated steatotic liver disease	18
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD	18
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3	18
	18
Functional involvement of endothelial lipase in hepatitis B virus infection	18
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis	18
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment	18
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease	18
Growth hormone deficiency and NAFLD: An overlooked and underrecognized link	18
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria	18
Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model	18
	18
Response to Tinospora cordifolia (Giloy)‐induced liver injury during the COVID‐19 pandemic—Multicenter nationwide study from India	18
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum	17
WNT7B Regulates Cholangiocyte Proliferation and Function During Murine Cholestasis	17
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha‐Methylacyl‐Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen‐Activated Protein Kinase	17
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage	17
Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration	17
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling	17
Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD)	17
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis	17
miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury	17
Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling	16
Genome‐Wide Association Study of NAFLD Using Electronic Health Records	16
A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis	16
Post-translational modifications drive the effects of HMGB1 in alcohol-associated liver disease	16
Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases	16
Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy	16
Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure	16
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors	16

Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study	16
Severe acute hepatitis of unknown etiology in a large cohort of children	16
The most impactful findings on liver cancer in 2023	16
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial	16
Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study	16
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target	16
Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review	16
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models	16
NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation	16
Long-term HBV infection of engineered cultures of induced pluripotent stem cell-derived hepatocytes	16
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018	15
Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease	15
Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC	15
High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases	15
COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality	15
	15
Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study	15
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	15
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	15
Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease	15
Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use	15
Ablation of high‐mobility group box‐1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling‐deficient mice	15
Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis	15
	15
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis	15
Activin B promotes the initiation and progression of liver fibrosis	15
Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death	15
Population screening for cirrhosis	15
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature	15
Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV	15
Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice	15
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	15
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	14
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	14
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	14
Neurogastroenterology and motility disorders in patients with cirrhosis	14
Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis	14
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	14
Direct Conversion of Human Endothelial Cells Into Liver Cancer‐Forming Cells Using Nonintegrative Episomal Vectors	14
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	14
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	14
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population	14
Assessing the risk of surgery in patients with cirrhosis	14
A versatile method to profile hepatitis B virus DNA integration	14
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	14
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	14
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	14
Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review	14
A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High‐Risk Primary Sclerosing Cholangitis	14
Alcohol‐Induced Liver Injury: Down‐regulation and Redistribution of Rab3D Results in Atypical Protein Trafficking	13
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	13
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study	13
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	13
Transcriptional Analysis of Liver Tissue Identifies Distinct Phenotypes of Indeterminate Pediatric Acute Liver Failure	13
Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development	13
Reply	13
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking	13
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	13
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	13
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	13
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD	13
Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link?	13
Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients	13
LKB1 acts as a critical brake for the glucagon‐mediated fasting response	13
Baveno VII for HCC: Are we there yet?	13
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	13
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	13
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	13
Issue Information	13
PRO‐C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD	13
Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease	13
Exosome-Like Nanoparticles From Lactobacillus rhamnosus GG Protect Against Alcohol-Associated Liver Disease Through Intestinal Aryl Hydrocarbon Receptor in Mice	12
Dual Targeting of Angipoietin‐1 and von Willebrand Factor by microRNA‐671‐5p Attenuates Liver Angiogenesis and Fibrosis	12
A windfall year for HCC: The most impactful clinical papers in 2023	12
Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list	12
Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese mice	12
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores	12
Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity	12
Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study	12
Recent TIPS increases postoperative mortality: A national cohort study	12
Issue Information	12
A River From the Liver: Detecting Hepatocyte Genomic DNA in Urine	12
High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder	12
Financial burden in a US cohort of patients with HCC	12
DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma	12
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study	12
Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study	12
Roles of RNA m6A modification in nonalcoholic fatty liver disease	12
Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH	12
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis	12
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study	12
Cytomegalovirus infection in patients with biliary atresia—further questions and possible solutions	12
Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis	12
	11
coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment	11